Amneal Pharmaceuticals Inc

AMRX

$5.80

Closing

▲2.02%

1D

▼-4.69%

YTD

Market cap

$1.78B

52 week high

$6.28

52 week low

$5.20

Volume

30,104

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$1.78B

Analysts' Rating

BUY

Price Target (Mean)

6.125

Total Analysts

5

P/E

91.58

Operating Margin

12.20%

Beta

Revenue Growth (Annual)

5.67%

52 week high

$6.28

52 week low

$5.20

Div. Yield

%

EPS Annual Growth

-25.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Amneal Pharmaceuticals, Inc. is a pharmaceutical company. The Company specializes in developing, manufacturing, marketing and distributing generic, injectables, biosimilars and branded specialty pharmaceutical products. Its segments include Generics, Specialty, and AvKARE. Its Generics segment includes approximately 250 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system (CNS) disorders, including Parkinson’s disease, and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies.